# A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

> **NCT02514083** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 29 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT02514083
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-12-09
- **Primary completion:** 2019-10-02
- **Final completion:** 2034-10-23
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02514083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02514083, "A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02514083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*